US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

60.98

-0.6309-1.02%

Volume:34.32K

Turnover:2.08M

Market Cap:284.78M

PE:19.95

High:61.59

Open:61.59

Low:60.44

Close:61.61

52wk High:64.10

52wk Low:39.36

Shares:4.67M

Float Shares:4.67M

Volume Ratio:2.72

T/O Rate:0.73%

Dividend:1.53

Dividend Rate:2.51%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Jiangsu Cowin Biotech Secures Class III Medical Device Certification for Clostridioides Difficile Detection Kit

Shanghai Kehua Bio-Engineering Secures Regulatory Approvals for Two New Diagnostic Kits

Roivant Sciences Ltd : Leerink Partners Raises Target Price to $52 from $42

THOMSON REUTERS

Brokerage Outlook: Medical Device Sectors Face Mixed Dynamics, Low-Value Consumables Shine

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)

Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer

MT Newswires Live

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

THOMSON REUTERS

Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities

Long-Term Bribery Involving 30+ Pharmaceutical Firms Prompts Hospital Response

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

Hospital Staff in Hebei Province Found Guilty of Accepting Bribes 46 Times Over 11 Years, Totaling 184 Million Yuan

MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds

Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/PTH/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":60.98,"timestamp":1789490111281,"preClose":61.6109,"halted":0,"volume":34322,"delay":0,"changeRate":-0.010240071156240276,"floatShares":4670000,"shares":4670000,"eps":3.057033,"marketStatus":"Trading","change":-0.6309,"latestTime":"09-15 12:37:28 EDT","open":61.585,"high":61.585,"low":60.44,"amount":2083446.30668,"amplitude":0.018584,"askPrice":61,"askSize":100,"bidPrice":60.89,"bidSize":300,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":61.6109,"sharesOutstanding":2480000,"nav":60.75567,"aum":283728978.9,"dividendRate":0.025057,"bidAskSpread":0.001903,"postHourTrading":{"tag":"盘后","latestPrice":61.66,"preClose":61.6109,"latestTime":"19:30 EDT","volume":13,"amount":800.5754,"timestamp":1789428602402,"change":0.0491,"changeRate":0.000797,"amplitude":0},"volumeRatio":2.7215,"impliedVol":0.1533,"impliedVolPercentile":0.745},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4670000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.7215,"shares":4670000,"dividePrice":1.528,"high":61.585,"amplitude":0.018584,"preClose":61.6109,"low":60.44,"week52Low":39.36,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":60.98,"committee":0.5,"eps":3.057033,"divideRate":0.025057,"volume":34322,"delay":0,"ttmEps":3.057033,"open":61.585,"prevYearClose":49.701,"prevWeekClose":60.7692,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":61.7173,"twentyDayClose":60.8616,"sixtyDayClose":52.9818},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140666287","title":"Jiangsu Cowin Biotech Secures Class III Medical Device Certification for Clostridioides Difficile Detection Kit","url":"https://stock-news.laohu8.com/highlight/detail?id=1140666287","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140666287?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:06","pubTimestamp":1789473999,"startTime":"0","endTime":"0","summary":"Jiangsu Cowin Biotech Co.,Ltd. (SH: 688426) has announced that its wholly-owned subsidiary, Jiangsu Jianwei Diagnostic Technology Co., Ltd., has received the Class III Medical Device Registration...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","MDEV","MEDX","159883","AGNG","IEIH","HART","BK1583","BK0239","BK1100","LGHT","PCR","688426","RSPH","09996","GDOC","PTH","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178547175","title":"Shanghai Kehua Bio-Engineering Secures Regulatory Approvals for Two New Diagnostic Kits","url":"https://stock-news.laohu8.com/highlight/detail?id=1178547175","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178547175?lang=en_us&edition=fundamental","pubTime":"2026-09-15 19:24","pubTimestamp":1789471463,"startTime":"0","endTime":"0","summary":"Shanghai Kehua Bio-Engineering Co., Ltd. (SZSE: 002022) has announced that it, along with its controlled subsidiary Suzhou Tianlong Biotechnology Co., Ltd., has received medical device registration...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","BK0188","BK0239","LGHT","AGNG","BK1100","BK1574","RSPH","09996","002022","GDOC","IEIH","BK1583","HART","BK0028","MEDX","LNGR","MDEV","PTH","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667649179","title":"Roivant Sciences Ltd : Leerink Partners Raises Target Price to $52 from $42","url":"https://stock-news.laohu8.com/highlight/detail?id=2667649179","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667649179?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:55","pubTimestamp":1789469735,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nFWN45707O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124014323","title":"Brokerage Outlook: Medical Device Sectors Face Mixed Dynamics, Low-Value Consumables Shine","url":"https://stock-news.laohu8.com/highlight/detail?id=1124014323","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124014323?lang=en_us&edition=fundamental","pubTime":"2026-09-15 10:16","pubTimestamp":1789438610,"startTime":"0","endTime":"0","summary":"According to a research report released by Zheshang Securities Co.,Ltd., the external environment and internal growth drivers across medical device sub-sectors are expected to diverge in the second...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","LNGR","BK1574","MEDX","BK0276","AGNG","BK1583","601878","BK1100","PTH","RSPH","159883","09996","IEIH","GDOC","HART","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","GNMX","GDOC","GH","LU0320765992.SGD","BK4535","BK4551","BK4585","GNOM","LU0109394709.USD","PTH","EKG","HELX","BK4196","FFOX","LFSC","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667966776","title":"Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667966776","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667966776?lang=en_us&edition=fundamental","pubTime":"2026-09-15 05:10","pubTimestamp":1789420212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and ArriVent BioPharma, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-arrivent-biopharma-inc-avbp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AVBP","IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","LU0128526141.USD","HCSG","BK4139","IE0009354923.USD","PTH","IE00BJJMRZ35.SGD","BK4585","BK4588","IE0009355771.USD","IE00B4R5TH58.HKD","BK4581","IDNA","LU0320765992.SGD","XBI","LU0029874061.USD","IE00BFTCPJ56.SGD","CANC","LU0889565916.HKD","XLV","IE00B2B36J28.USD","IE0002141913.USD","BBH","BK4137","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695932","title":"Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695932","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695932?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:35","pubTimestamp":1789418122,"startTime":"0","endTime":"0","summary":"Revolution Medicines  said Monday that the US Food and Drug Administration has given breakthrough therapy designation to Rasonque plus chemotherapy to treat pancreatic cancer.The company said Rasonque was recently approved by the US FDA to treat adults with metastatic pancreatic cancer who have received at least one systemic therapy or who are not candidates for multiagent systemic therapy.Revolution said the use of Rasonque plus chemotherapy for treatment-naive metastatic pancreatic adenocarcinoma is still investigational, with safety and efficacy not yet established.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","IE0009354923.USD","BK4588","IE0009355771.USD","PTH","LABU","RVMD","IDNA","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BBH","IE00BJT1NW94.SGD","IE00B2B36J28.USD","CANC","LU0889565916.HKD","LU0109394709.USD","BK4585","BK4139","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667953426","title":"Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2667953426","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667953426?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:15","pubTimestamp":1789416936,"startTime":"0","endTime":"0","summary":"Revolution Medicines (RVMD) announced that the FDA has granted Breakthrough Therapy Designation to Rasonque, the company’s RAS multi-selective inhi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/revolution-medicines-granted-breakthrough-therapy-designation-to-rasonque-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/revolution-medicines-granted-breakthrough-therapy-designation-to-rasonque-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","LU0109394709.USD","RVMD","BK4139","IE0009354923.USD","PTH","IE00BJJMRZ35.SGD","BK4588","BK4585","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","LU0320765992.SGD","IE00BFTCPJ56.SGD","CANC","LU0889565916.HKD","IE00B2B36J28.USD","IE0002141913.USD","BBH","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4585","GNOM","LU0109394709.USD","LU0320765992.SGD","FFOX","PTH","GH","LFSC","BK4588","HELX","BK4535","LU0889565916.HKD","GNMX","EKG","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667769375","title":"Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667769375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667769375?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA3JTDPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","RVMD","BK4139","IE0009355771.USD","IE00B4R5TH58.HKD","IDNA","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","LU0109394709.USD","IE0009354923.USD","CANC","PTH","IE00B2B36J28.USD","BBH","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466962","title":"Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466962?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:11","pubTimestamp":1789391469,"startTime":"0","endTime":"0","summary":"Bellevue flags US healthcare innovation as driving fresh investment opportunitiesBellevue Group AG flagged patient-outcome innovation as a key driver of healthcare investment opportunities from recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL8lm3Sh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","BK4082","BK4139","LU0006061336.USD","LU0648000940.SGD","LU1150488218.USD","BK4588","LU1059921491.USD","LU1894683348.USD","BK4585","LU1854103824.USD","LQDA","LU0130518102.USD","LU0266013472.USD","LU0289961442.SGD","LU0511384066.AUD","BK4007","LU1571399168.USD","LU0162691827.USD","LU0985320562.USD","LU0477156797.USD","LU1894683264.USD","LU0068578508.USD","BDX","LU1489326972.SGD","IHI","LU0433182093.SGD","BK4532","LU1150488135.SGD","LU0289739343.SGD","LU1699723380.USD","LU0072461881.USD","UTHR","ROIV","BK4504","PTH","LU0985489474.SGD","IE00BFXG1179.USD","LU0130103400.USD","LU1201861165.SGD","LU0878866978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122259450","title":"Long-Term Bribery Involving 30+ Pharmaceutical Firms Prompts Hospital Response","url":"https://stock-news.laohu8.com/highlight/detail?id=1122259450","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122259450?lang=en_us&edition=fundamental","pubTime":"2026-09-14 12:21","pubTimestamp":1789359679,"startTime":"0","endTime":"0","summary":"On September 13, China's National Healthcare Security Administration released a report detailing commercial bribery cases in medical institutions' pharmaceutical procurement. The report revealed that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RSPH","LGHT","LNGR","HART","GDOC","09996","BK1583","BK1574","MEDX","BK1100","MDEV","AGNG","PTH","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668081","title":"Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668081","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668081?lang=en_us&edition=fundamental","pubTime":"2026-09-14 01:20","pubTimestamp":1789320035,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Cooper Co (COO) with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-revolution-medicines-rvmd-and-cooper-co-coo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B4R5TH58.HKD","BK4137","IE0002141913.USD","LU2272731782.SGD","IE0009355771.USD","LU0320765992.SGD","LABU","IDNA","CANC","PTH","LU2272731600.USD","IE00BJT1NW94.SGD","LU1992135472.HKD","LU0128526141.USD","IE00BJJMRZ35.SGD","HCSG","COO","LU1992135399.USD","BK4581","XLV","XBI","GB00BDT5M118.USD","BBH","IE00B2B36J28.USD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","BK4585","LU0029874061.USD","RVMD","BK4588","LU2211815571.USD","IE0009354923.USD","BK4139","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173526187","title":"Hospital Staff in Hebei Province Found Guilty of Accepting Bribes 46 Times Over 11 Years, Totaling 184 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1173526187","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173526187?lang=en_us&edition=fundamental","pubTime":"2026-09-13 09:40","pubTimestamp":1789263647,"startTime":"0","endTime":"0","summary":"China's medical insurance regulator, which set up a credit evaluation system for pharmaceutical pricing and procurement in August 2020, has uncovered a significant case of commercial bribery in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HART","MDEV","LNGR","BK1583","MEDX","BK1100","AGNG","IEIH","BK1161","BK1574","LGHT","PTH","09939","RSPH","09996","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188732548","title":"MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=1188732548","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188732548?lang=en_us&edition=fundamental","pubTime":"2026-09-11 15:40","pubTimestamp":1789112453,"startTime":"0","endTime":"0","summary":"MEDCAPTAIN has officially launched its global offering on the Hong Kong stock exchange. Originating from a small infusion equipment manufacturer, the company has leveraged capital support and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IEIH","BK1100","159883","BK1574","RSPH","KCE","09996","PTH","BK4588","MYLD","LGHT","BK1583","02041","MDEV","AGNG","XMMO","HART","GDOC","LNGR","CALF","BK4585","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512383","title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512383","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512383?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088474,"startTime":"0","endTime":"0","summary":"Roivant Sciences director Meghan FitzGerald disposes of USD 798,000 in common sharesRoivant director Meghan FitzGerald exercised stock options for 20,000 common shares at USD 8.8 on Sept. 8.She sold 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL33g4Z7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Director Meghan FitzGerald Disposes of USD 798,000 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666516010","title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666516010","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666516010?lang=en_us&edition=fundamental","pubTime":"2026-09-11 05:53","pubTimestamp":1789077203,"startTime":"0","endTime":"0","summary":"Revolution Medicines director Lorence H. Kim disposes of 17,090 common shares worth USD 3.57 millionDirector Lorence H. Kim disclosed sales of 17,090 Revolution Medicines common shares on Sep. 8, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL1wDHJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","IE00BFTCPJ56.SGD","PTH","LU0889565916.HKD","RVMD","CANC","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009354923.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4139","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666518829","title":"Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666518829","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666518829?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:40","pubTimestamp":1789065600,"startTime":"0","endTime":"0","summary":"Revolution Medicines barely had time to celebrate the landmark approval of its pancreatic cancer pill before Wall Street demanded to know what's next.Late last month, regulators approved daraxonrasib ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU1983299246.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU1868836591.USD","BK4559","LU2133065610.SGD","LU0432979614.USD","LU2360032135.SGD","IHE","BK4534","IE0002141913.USD","LU0267386448.USD","LU0456855351.SGD","LU1868836757.USD","LU1236620750.USD","LU2125154935.USD","LU1093756168.USD","BK4585","LU1670710588.SGD","BBH","LU1430594728.SGD","IE00BSNM7G36.USD","LU0096364046.USD","LU0882574055.USD","IE0009354923.USD","LU1670711040.USD","IE0009355771.USD","BMY","IDNA","PTH","IE00BFXG1179.USD","CANC","LU0109394709.USD","LU0985481810.HKD","LU0868494617.USD","LU0114720955.EUR","LU1718418525.SGD","LU0237698245.USD","FTXH","LU0306806265.USD","LU1571399168.USD","BK4588","LU1032466523.USD","BK4581","LU1236620834.HKD","LU1585245621.USD","IE00BFTCPJ56.SGD","RVMD","LU1868837300.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666359288","title":"Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666359288","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666359288?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:29","pubTimestamp":1789054182,"startTime":"0","endTime":"0","summary":"Revolution Medicines  could see strong long-term growth from Rasonque sales, expansion into earlier treatment, and new drugs and combination therapies pending upcoming trial results, Morgan Stanley said in a note Thursday.Morgan Stanley models about $12 billion in peak risk-adjusted sales across the company's drug portfolio by 2036, with potential sales of about $18 billion before adjusting for development risks, according to the note.The analysts see Rasonque as the company's main commercial base, while zoldonrasib, elironrasib and earlier-stage drugs could provide additional  sources of growth and reduce reliance on one treatment, while combination treatments could become an important long-term driver by helping the company reach patients earlier in treatment and expand into more cancer types.The next 12 to 18 months will include the US launch of Rasonque, updates in colorectal cancer, progress from early-stage drugs and several late-stage studies, though weaker drug uptake or disapp","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RVMD","CANC","BBH","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","IE00B2B36J28.USD","PTH","IDNA","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE0009354923.USD","BK4139","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666996625","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666996625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666996625?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:30","pubTimestamp":1789047034,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-axsome-therapeutics-axsm-and-ocugen-ocgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-axsome-therapeutics-axsm-and-ocugen-ocgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","XBI","OCGN","XLV","AXSM","BK4563","LU0128526141.USD","LU0029874061.USD","HCSG","ZYME","BK4588","BK4007","LABU","LU2324357040.USD","BK4505","BK4139","BK4585","BK4568","PTH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}